


Therapiealgorithmus der Deutschen Atemwegsliga

für das nicht-kleinzellige Lungenkarzinom (NSCLC)
Stadium IV



Deutsche Atemwegsliga e.V.

NSCLC mit Treibermutation



	Freiname	Handelsname
EGFR-TKI	Afatinib	Giotrif
	Erlotinib	Tarceva
	Gefitinib	Iressa
EGFR-T790M-TKI	Osimertinib	Tagrisso
ALK-TKI	Crizotinib	Xalkori
	Alectinib	Alecensa
	Ceritinib	Zykadia
VEGF-AK	Bevacizumab	Avastin
B-RAF-TKI	Dabrafenib	Tafinlar
MEK-TKI	Trametinib	Mekinist

Abkürzungen:

B-RAF (Onkogen) | **EGFR** (Epidermal Growth Factor Receptor) | **ALK** (Anaplastische Lymphom-Kinase) | **PD-L1** (Programmed Death-Ligand 1)
KI (Kontraindikation) | **VEGF** (Vascular Endothelial Growth Factor) | **ROS** (Reactive Oxygen Species) | **TKI** (Tyrosinkinaseinhibitor)
MEK (Mitogen-Activated Extracellular Signal Regulated Kinase)


Therapiealgorithmus der Deutschen Atemwegsliga

für das nicht-kleinzellige Lungenkarzinom (NSCLC)
Stadium IV



Deutsche Atemwegsliga e.V.

NSCLC ohne Treibermutation



	Freiname	Handelsname
Immunonkologika	Atezolizumab	Tecentric
	Nivolumab	Opdivo
	Pembrolizumab	Keytruda
VEGFR-AK	Ramucirumab	Cyramza
VEGFR-TKI	Nintedanib	Vargatef
EGFR-AK	Necitumumab	Portrazza

Abkürzungen:

EGFR (Epidermal Growth Factor Receptor)
VEGF (Vascular Endothelial Growth Factor)

ALK (Anaplastische Lymphom-Kinase)
ROS (Reactive Oxygen Species)

PD-L1 (Programmed Death-Ligand 1)
TKI (Tyrosinkinaseinhibitor)